Comparison of Laboratory Values and Adverse Effects between Cyclosporine and Tacrolimus-based Regimens in Renal Transplant Patients:

• 발행기관: 대한약학회
• 저자명: Hae Jeong Kim Young Mo Yang In Cho e Eun Joo Choi
• 간행물 정보: 『약학회지』제61권 제3호(2017년), 164~170쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2017.06.30

영문 초록

Multidrug combination of immunosuppressive agents has been used to achieve an optimal immunosuppression and prevent adverse effects (AEs) of immunosuppressant in kidney transplant patients. Cyclosporine (CsA) and tacrolimus (TAC) are mostly used immunosuppressive drugs out of preferred immunosuppressive regimens for the prevention of rejection after kidney transplantation. Due to variable pharmacokinetic profiles and frequent AEs with immunosuppressants such as CsA, TAC, and mycophenolate mofetil (MMF), the studies related to therapeutic drug monitoring (TDM) of immunosuppressive regimen have continuously been researched. The aims of this study were to analyze monitoring and AEs on IMRs in renal transplant patients. The study was conducted at the teaching hospital in Gwangju, Korea. Medical charts of 58 renal transplant patients selected based on inclusion criteria between January 2002 and July 2013 were reviewed retrospectively. Among total 58 patients, 38 were included in the analysis. They were divided into two groups: CsA +MMF + steroid group (CsA group, n=28) and TAC +MMF + steroid (TAC group, n=10) group. As a result, the triglyceride level of the CsA group was significantly increased compared with that of the TAC group at 3, 9 and 12 months (p=0.008, p=0.007, p=0.033, respectively). The dyslipidemia complications of CsA group were higher than that of TAC group at 3, 6, and 12 month after transplantation (p=0,044, p=0.043, p=0.048, respectively). The AST level of CsA group was significantly increased compared with that of the TAC group at 3 month (p=0.002). This study also showed that a TACbased regimen tended to increase a blood glucose level during 12 months. This study determined that patients with a CsAbased regimen should be closely monitored regarding lipid profiles and liver function tests, and those with a TAC-based regimen should be cautiously monitored about blood glucose levels to prevent complications by AEs during immunosuppressive therapy.

목차

Eexperimental Methods

Results

Discussion

Conclusion

Acknowledgements

References

키워드

Immunosuppressive Agents Monitoring Factors Adverse Effects Kidney Transplantation